EQL Pharma is a pharmaceutical company. Currently, the focus is on development of niche and specialised pharmaceuticals, including everything from pharma for the treatment of diabetes, enlargement of blood vessels, as well as various infections and allergies. Primarily business is found in the Nordic market. EQL Pharma was founded in 2006 and is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Cadila Pharmaceuticals Ltd | 30,00 | 30,00 | 2024-03-26 |
| Christer Fåhraeus | 24,21 | 24,21 | 2024-03-26 |
| SEB Fonder | 4,33 | 4,33 | 2024-03-26 |
| Avanza Pension | 3,63 | 3,63 | 2024-03-26 |
| Consensus Asset Management | 2,79 | 2,79 | 2024-03-31 |
| Nordnet Pensionsförsäkring | 2,43 | 2,43 | 2024-03-26 |
| Sten Irwe | 1,71 | 1,71 | 2024-03-26 |
| Carnegie Fonder | 1,51 | 1,51 | 2024-03-31 |
| Cliens Fonder | 1,06 | 1,06 | 2024-03-26 |
| Martin Søkjer-Petersen | 1,02 | 1,02 | 2024-03-26 |
2024-05-14 Bokslutskommuniké 2024
2024-08-08 Delårsrapport 2025-Q1
2024-08-19 Årsstämma 2024
